Stay updated with breaking news from Jamese Ip. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.
Six in 10 patients had heart rate restored to normal within 30 minutes
Investigational etripamil nasal spray is well tolerated for self-treating recurrent episodes of PSVT without medical supervision.
A fast-acting medication delivered as a nasal spray may someday allow patients with intermittent rapid heartbeats to treat it themselves as soon as they develop symptoms, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
The safety and tolerability of etripamil, an investigational nasal spray for paroxysmal supraventricular tachycardia (PSVT), are maintained in new data from the NODE-302 extension study.